Apomorphine for the acute treatment of "off" episodes in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 14, Issue 2, 2008, Pages 85-92

  Stacy, Mark ^a   Silver, Dee ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Coastal Neurological Medical Group ^*  (United States)

Author keywords

"Off" episodes; Acute; Apomorphine; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA METHYL ESTER; LISURIDE; PLACEBO; TRIMETHOBENZAMIDE;

CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; HUMAN; INJECTION SITE REACTION; LONG TERM CARE; MORNING DOSAGE; MOTOR DYSFUNCTION; MOUTH ULCER; NAUSEA; NOSE IRRITATION; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHINORRHEA; SEDATION; SIDE EFFECT; SOMNOLENCE; STOMATITIS; TREATMENT RESPONSE; VERTIGO; VOMITING; YAWNING;

ANTIPARKINSON AGENTS; APOMORPHINE; HUMANS; INJECTIONS, SUBCUTANEOUS; PARKINSON DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES;

EID: 44249093494     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2007.07.016     Document Type: Review

References (40)

1. Rajput M.L., and Rajput A.H. Epidemiology of parkinsonism. Parkinson's disease: diagnosis and clinical management (2002), Demos, New York 31-40
2. Stacy M. Pharmacotherapy for advanced Parkinson's disease. Pharmacotherapy 20 (2000) 8S-16S
3. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16 (2001) 448-458
4. Stacy M., Bowron A., Guttman M., Hauser R., Hughes K., Larsen J.P., et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 20 (2005) 726-733
5. Anthony J., Spears J., and Van Lunen B. Implications of motor fluctuations in Parkinson's disease patients on chronic therapy (IMPACT): results from an observational registry. Mov Disord 20 (2005) S146
6. Wilson R.E., Spears J.B., and Van Lunen B.E. Implications of Motor fluctuations in Parkinson's patients on Chronic Therapy (IMPACT) registry: relationship between Hoehn & Yahr stage and patient- and disease-related characteristics. Mov Disord 21 Suppl. 13 (2006) S95
7. Stacy M., Spears J.B., and Van Lunen B.E. Implications of Motor fluctuations in Parkinson's patients on Chronic Therapy (IMPACT) registry: comparison of patient- and physician-reported data. Mov Disord 21 Suppl. 13 (2006) S92
8. Chapuis S., Ouchchane L., Metz O., Gerbaud L., and Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 20 (2005) 224-230
9. Wilson R.E., Silver D., Spears J.B., and Van Lunen B.E. Implications of Motor fluctuations in Parkinson's patients on Chronic Therapy (IMPACT) registry: quality of life (QOL) data. Mov Disord 21 Suppl. 13 (2006) S151
10. Swope D.M. Rapid treatment of "wearing off" in Parkinson's disease. Neurology 62 (2004) S27-S31
11. Metman L.V., Hoff J., Mouradian M.M., and Chase T.N. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord 9 (1994) 463-465
12. Pappert E.J., Goetz C.G., Niederman F., Ling Z.D., Stebbins G.T., and Carvey P.M. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology 47 (1996) 1493-1495
13. Data on file. Vernalis Pharmaceuticals Inc. Study APO301.
14. Deffond D., Durif F., and Tournilhac M. Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes. J Neurol Neurosurg Psychiatry 56 (1993) 101-103
15. Dewey Jr. R.B., Hutton J.T., LeWitt P.A., and Factor S.A. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 58 (2001) 1385-1392
16. Durif F., Deffond D., and Tournilhac M. Efficacy of sublingual apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry 53 (1990) 1105
17. Frankel J.P., Lees A.J., Kempster P.A., and Stern G.M. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 53 (1990) 96-101
18. Pietz K., Hagell P., and Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry 65 (1998) 709-716
19. Poewe W., Kleedorfer B., Gerstenbrand F., and Oertel W. Subcutaneous apomorphine in Parkinson's disease. Lancet 1 (1988) 943
20. Stibe C.M., Lees A.J., Kempster P.A., and Stern G.M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1 (1988) 403-406
21. van Laar T., Jansen E.N., Essink A.W., Neef C., Oosterloo S., and Roos R.A. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease. Clin Neurol Neurosurg 95 (1993) 231-235
22. Apokyn (apomorphine hydrochloride injection) prescribing information. Morristonw, NJ: Vernalis Pharmaceuticals Inc.; 2004.
23. Koller W. APO303 investigators. A double-blind placebo-controlled study of the efficacy of a single dose of subcutaneous apomorphine in Parkinson's disease. Neurology 62 (2004) A329
24. Dewey Jr. R.B. Management of motor complications in Parkinson's disease. Neurology 62 (2004) S3-S7
25. Factor S.A. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology 62 (2004) S12-S17
26. Hardie R.J., Lees A.J., and Stern G.M. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain 107 Pt. 2 (1984) 487-506
27. Colosimo C., Merello M., Hughes A.J., Sieradzan K., and Lees A.J. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 60 (1996) 634-637
28. Steiger M.J., Stocchi F., Bramante L., Ruggieri S., and Quinn N.P. The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease. Clin Neuropharmacol 15 (1992) 501-504
29. Merello M., Pikielny R., Cammarota A., and Leiguarda R. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study. Clin Neuropharmacol 20 (1997) 165-167
30. Steiger M.J., Stocchi F., Carta A., Ruggieri S., Agnoli A., Quinn N.P., et al. The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease. Clin Neuropharmacol 14 (1991) 241-244
31. Djaldetti R., and Melamed E. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Ann Neurol 39 (1996) 400-404
32. Pfeiffer R.F., Gutmann L., Hull Jr. K.L., Bottini P.B., Sherry J.H., and and The APO302 Study Investigators. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism Relat Disord 13 2 (2007) 93-100
33. Ostergaard L., Werdelin L., Odin P., Lindvall O., Dupont E., Christensen P.B., et al. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 58 (1995) 681-687
34. Dewey Jr. R.B., Maraganore D.M., Ahlskog J.E., and Matsumoto J.Y. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease. Mov Disord 13 (1998) 782-787
35. Montastruc J.L., Rascol O., Senard J.M., Gualano V., Bagheri H., Houin G., et al. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin Neuropharmacol 14 (1991) 432-437
36. Hughes A.J., Webster R., Bovingdon M., Lees A.J., and Stern G.M. Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations. Clin Neuropharmacol 14 (1991) 556-561
37. Ondo W., Hunter C., Almaguer M., Gancher S., and Jankovic J. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin Neuropharmacol 22 (1999) 1-4
38. Kurth M.C. Using liquid levodopa in the treatment of Parkinson's disease. A practical guide. Drugs Aging 10 (1997) 332-340
39. Hughes A.J., Bishop S., Kleedorfer B., Turjanski N., Fernandez W., Lees A.J., et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 8 2 (1993) 165-170
40. Bowron A. Practical considerations in the use of apomorphine injectable. Neurology 62 (2004) S32-S36